Drug combo shows potential in treating hepatitis C

10/14/2010 | Reuters

The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI